| | Title | Author(s) | Year | View Count | | 1 |  | What is the best end point for hepatitis b treatment? | Lai, CL; Yuen, MF | 2008 | 287 |
| 2 | | Natural history of hepatitis-related hepatocellular carcinoma | But, DYK; Lai, CL; Yuen, MF | 2008 | 102 |
| 3 |  | Efficacy of entecavir in nucleoside-naefve patients with mildly elevated ALT | Gordon, SC; Han, SH; Chang, TT; Lai, CL; Han, KH; Chao, YC; Tan, CK; Sievert, W; Tanwandee, T; Neo, BL | 2008 | 98 |
| 4 | | Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity | Mak, CM; Lam, CW; Tam, S; Lai, CL; Chan, LY; Fan, ST; Lau, YL; Lai, JY; Yuen, P; Hui, J; Fu, CC; Wong, KS; Mak, WL; Tze, K; Tong, SF; Lau, A; Leung, N; Hui, A; Cheung, KM; Ko, CH; Chan, YK; Ma, O; Chau, TN; Chiu, A; Chan, YW | 2008 | 212 |
| 5 | | The importance of HBV DNA monitoring | Fung, JYY; Lai, CL; Yuen, RMF | 2008 | 72 |
| 6 |  | Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels | Yuen, MF; Tanaka, Y; Shinkai, N; Poon, RT; But, DYK; Fong, DYT; Fung, J; Wong, DKH; Yuen, JCH; Mizokami, M; Lai, CL | 2008 | 428 |
| 7 | | Updates in the treatment of chronic hepatitis B | Lai, CL; Fung, J; Yuen, MF | 2008 | 137 |
| 8 | | Drug Profile – Telbivudine | Fung, JYY; Lai, CL; Yuen, RMF | 2008 | 131 |
| 9 | | Chronic hepatitis B - New goals, new treatment | Lai, CL; Yuen, MF | 2008 | 144 |
| 10 | | Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity (Journal of Human Genetics (2008) 53 (55-63) DOI: 10.1007/s10038-007-0218-2) | Mak, CM; Lam, CW; Tam, S; Lai, CL; Chan, LY; Fan, ST; Lau, YL; Lai, ST; Yuen, P; Hui, J; Fu, CC; Wong, KS; Mak, WL; Tze, K; Tong, SF; Lau, A; Leung, N; Hui, A; Cheung, KM; Ko, CH; Chan, YK; Ma, O; Chau, TN; Chiu, A; Chan, YW | 2008 | 76 |
| 11 | | The authors reply | Lai, CL; Gane, E; Brown, NA | 2008 | 46 |
| 12 | | Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response | Yuen, MF; Fong, DYT; Wong, DKH; Yuen, JCH; Fung, J; Lai, CL | 2007 | 332 |
| 13 | | Intestinal tuberculosis mimicking fistulizing Crohn's disease | Wong, WM; Lai, KC; Yiu, WC; Wong, BCY; Chan, FL; Lai, CL | 2007 | 138 |
| 14 | | Quantitative analysis of HBV cccDNA from clinical specimens: Correlation with clinical and virological response during antiviral therapy | Bourne, EJ; Dienstag, JL; Lopez, VA; Sander, TJ; Longlet, JM; Hall, JG; Kwiatkowski, RW; Wright, T; Lai, CL; Condreay, LD | 2007 | 113 |
| 15 | | Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial | Chan, HLY; Heathcote, EJ; Marcellin, P; Lai, CL; Cho, M; Moon, YM; Chao, YC; Myers, RP; Minuk, GY; Jeffers, L; Sievert, W; Bzowej, N; Harb, G; Kaiser, R; Qiao, XJ; Brown, NA; Crawford, D; Lim, SG; Chutaputti, A; Poynard, T | 2007 | 138 |
| 16 | | Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: A case-control study | Fung, J; Yuen, MF; Yuen, JCH; Wong, DKH; Lai, CL | 2007 | 109 |
| 17 | | Combination therapy for chronic hepatitis B: Simultaneous or sequential? | Yuen, MF; Lai, CL | 2007 | 54 |
| 18 | | Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: Implication for early HBeAg seroconversion | Yuen, MF; Wong, DKH; Zheng, BJ; Chan, CCS; Yuen, JCH; Wong, BCY; Lai, CL | 2007 | 70 |
| 19 | | Prediction of treatment outcomes for lamivudine | Yuen, MF; Lai, CL | 2007 | 28 |
| 20 | | Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results | Schiff, E; Lai, CL; Hadziyannis, S; Nuehaus, P; Terrault, N; Colombo, M; Tillmann, H; Samuel, D; Zuezem, S; Villenueve, JP; Arteburn, S; BorrotoEsoda, K; Brosgart, C; Chuck, S; Shakil, AO; Fung, J; Alberti, A; Lok, A; Picciotto, A; Torre, F; Riely, C; Trepo, C; Bizollon, T; BottaaFridlund, D; Gerolami, R; Douglas, D; Ranjan, D; Faust, D; Trojan, J; Gane, E; Villa, E; Boarino, M; Sokal, E; Starkel, P; Bonino, F; Maurizio, B; Gordon, F; Pratt, J; Berr, F; Schiefke, I; McCaughan, G; Strasser, S; Dusheiko, G; Pageaux, GP; Larrey, D; Pastore, G; Santantonio, T; Alexander, G; Woodall, T; Van Vlierberghe, H; Colle, I; Harley, H; Guggenheim, J; MyxStaccini, A; Metreau, JM; Mavier, P; Vierling, J; Tran, T; Girgrah, N; Nyberg, L; Yuen, MF; Ma, M; Balnco, MD; Merli, M; Tanzilli, P; Angelico, M; Di Paolo, D; Rizzetto, M; Marzano, A; Lampertico, P; Prieto, M; Berenguer, M; Felder, M; Sterneck, M; Willems, M; Charlton, M; Gunneson, T; Ritter, M; Voight, M; Swift, J; Shiffman, M; Tassopoulos, N; Klissas, I; Naourmov, N; Chamouard, P; Marcellin, P; Durand, F; Angus, P; Nathan, C; Toniutto, P; Fumo, E; Andreone, P; Cursaro, C; Barcena, R; Hoz, FG; Zachoval, R; Christina, M; De Man, RA; Metselaar, H | 2007 | 142 |
|
